Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,367 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

NCT00775138
View directory record Official record
Conditions
Bronchiectasis
Interventions
280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™, Matching Placebo for Cohort 2
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 30, 2026, 12:02 PM EDT
Terminated Not applicable Interventional

Targeted Gown and Glove Intervention in Nursing Homes

NCT04200508
View directory record Official record
Conditions
Staphylococcus Aureus, Carbapenem Resistant Gram Negative Bacteria
Interventions
Targeted gown and gloves use
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Not applicable Interventional

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000638
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Nontypeable H. Influenzae in Healthy Adults

NCT00905385
View directory record Official record
Conditions
Haemophilus Influenzae (NTHI)
Interventions
NTHi Strain 2019
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

NCT00634049
View directory record Official record
Conditions
Aspergillosis, Invasive Fungal Infections
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BBOT: Bacterial Burden in Ortho Trauma Procedures

NCT03126448
View directory record Official record
Conditions
Orthopaedic Trauma Infections
Interventions
Highly Sensitive Assays
Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

NCT04801420
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
19
States / cities
Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05420961
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
717 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects

NCT04079790
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 30, 2026, 12:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

TEDDY - The Environmental Determinants of Diabetes in the Young

NCT00279318
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
0 Months to 4 Months
Enrollment
8,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2025
U.S. locations
4
States / cities
Denver, Colorado • Gainesville, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 30, 2026, 12:02 PM EDT
Active, not recruiting Phase 2 Interventional

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
30
States / cities
Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Recruiting Phase 1 Interventional

Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

NCT07828860
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Soquelitinib
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
West Lafayette, Indiana • Bowling Green, Kentucky • Owensboro, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1Phase 2 Interventional

Treating Post-Lyme Disease Syndrome With Acetogenins

NCT04078841
View directory record Official record
Conditions
Post-Lyme Disease Syndrome (PLDS)
Interventions
ReaLife+ (RLP), Inert Brown powder
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 30, 2026, 12:02 PM EDT
Recruiting No phase listed Observational

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

NCT07077213
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
18F-FAPI-74
Combination Product
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
CB-183,315, Placebo, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

NCT07104162
View directory record Official record
Conditions
Bacterial Infections
Interventions
Cefiderocol/Xeruborbactam
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Withdrawn Not applicable Interventional

Vitamin D in Active Tuberculosis (TB) Study

NCT00788320
View directory record Official record
Conditions
Tuberculosis
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

NCT01371656
View directory record Official record
Conditions
Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
levofloxacin
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
78
States / cities
Little Rock, Arkansas • Downey, California • Duarte, California + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]

NCT03869333
View directory record Official record
Conditions
Diarrhea
Interventions
Invaplex[AR-DETOX], Placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 30, 2026, 12:02 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing

NCT04574752
View directory record Official record
Conditions
Staphylococcus Aureus, Next Generation Sequencing, Total Joint Arthroplasty
Interventions
next generation sequencing
Diagnostic Test
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 30, 2026, 12:02 PM EDT
Not yet recruiting Phase 2 Interventional

Fluorometholone Study

NCT07308938
View directory record Official record
Conditions
Keratitis Bacterial, Corneal Ulcer (Diagnosis)
Interventions
Adjunctive Topical Fluorometholone (FML) 0.1%, Standard Topical Antibiotic Therapy
Drug
Lead sponsor
Vishal Jhanji
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin

NCT00000778
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyridoxine hydrochloride, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 30, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VHA Clinicians and Bioterror Events: Interactive Web-based Learning

NCT00123396
View directory record Official record
Conditions
Smallpox, Anthrax
Interventions
BioCASES and BioTESTS
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 30, 2026, 12:02 PM EDT